The Aryl Ring Or Aryl Ring System Is Bonded Directly To Another Ring Or Ring System Patents (Class 514/650)
-
Publication number: 20080058250Abstract: The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising a phosphate binder and another pharmaceutically active ingredient. The other pharmaceutically active ingredient is selected from a group consisting of antihypertensives, calcitrol, vitamin D analogues, lipid restriction products, potassium salts, treatments for anemia and alkalization compounds.Type: ApplicationFiled: August 17, 2006Publication date: March 6, 2008Inventors: Allison Wren, Roy Graham, Randy McElreath, Michael Molnar
-
Publication number: 20070259041Abstract: Solid dosage formulations are provided for a compound having the formula: wherein R2 is Cl, F, Br, CH3, CF3, SCH3, NHCH3, NO2, CN, OH, OC1—C6 alkyl, or substituted OC1—C6 alkyl, or a prodrug or a pharmaceutically acceptable salt thereof. Formulations for tablets and multiparticulates containing a compound according to the above formula, a rate controlling component, and a binder are described, including formulations containing a seal coating, release rate controlling coating, and/or enteric coating. Pharmaceutical uses and kits thereof are also described.Type: ApplicationFiled: May 3, 2007Publication date: November 8, 2007Applicant: WyethInventors: Christopher Richard Diorio, Eric Ehrnsperger, Syed M. Shah
-
Patent number: 7273889Abstract: The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.Type: GrantFiled: September 25, 2002Date of Patent: September 25, 2007Assignee: Innovative Drug Delivery Systems, Inc.Inventors: Fred H. Mermelstein, Randi Albin
-
Patent number: 7273952Abstract: Substituted C-cyclohexylmethylamine derivatives, methods for the production thereof, pharmaceuticals containing said compounds, the use of substituted C-cyclohexylmethylamine derivatives for producing pharmaceuticals, and method of pain treatment using the pharmaceuticals.Type: GrantFiled: March 31, 2003Date of Patent: September 25, 2007Assignee: Gruenenthal GmbHInventors: Bernd Sundermann, Corinna Maul, Helmut Buschmann, Michael Finkam, Babette-Yvonne Koegel
-
Patent number: 7256185Abstract: The treatment of an estrogen sensitive condition by the administration of a selective estrogen receptor modulator is improved by additionally administering a progestationally active compound to the recipient. The additional agent can express both progestational and androgenic activity or an androgenically active material can be employed, if desired. Additionally, clomiphene in an array of isomeric ratios (EN:ZU) can be used alone for prevention of osteoporosis, maintenance of a healthful blood lipid profile, and prevention of breast tumors, or to sustain amenorrhea.Type: GrantFiled: May 18, 1999Date of Patent: August 14, 2007Assignee: Eastern Virginia Medical SchoolInventor: Gary D. Hodgen
-
Patent number: 7220783Abstract: The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or weakly suppresses the production of IgG, IgM and/or IgA which are produced at the same time, a compound of the formula (I): wherein R1–R13 are hydrogen, halogen, lower alkyl, lower alkoxy or the like, X is —O—, —CH2—, —NR14— or —S(O)p- and Y is lower alkyl, lower alkenyl or the like, a process for producing the same and a pharmaceutical composition comprising the same.Type: GrantFiled: November 12, 2003Date of Patent: May 22, 2007Assignee: Shionogi & Co., Ltd.Inventors: Kenji Kawada, Mitsuaki Ohtani, Ryuji Suzuki, Akinori Arimura
-
Patent number: 7169817Abstract: The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them. Compounds according to the present invention are based upon the chemical formula: wherein the substituents have the values mentioned herein.Type: GrantFiled: May 27, 2003Date of Patent: January 30, 2007Assignee: IRM LLCInventors: Shifeng Pan, Nathanael S. Gray, Wenqui Gao, Klaus Hinterding, Sophie Lefebvre, Yuan Mi, Peter Nussbaumer, Wei Wang, Federic Zecri, Fan Yi, Lawrence Blas Perez, Kenneth Richad la Montagne, Peter Ettmayer
-
Patent number: 7135497Abstract: ?2-agonists, such as clenbuterol and salbutamol can enhance the recovery of locomotive function and/or neuromuscular strength following spinal cord injuries or as a result of degenerative neural conditions such as Mnd. Pharmacological compositions for treating spinal cord injuries and degenerative neural conditions are also provided.Type: GrantFiled: July 7, 2000Date of Patent: November 14, 2006Assignee: New York Medical CollegeInventors: Richard J. Zeman, Joseph D. Etlinger
-
Patent number: 7105701Abstract: Disclosed are multibinding compounds which are ?2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.Type: GrantFiled: May 10, 2005Date of Patent: September 12, 2006Assignee: Theravance, Inc.Inventors: Edmund J. Moran, Seok-Ki Choi
-
Patent number: 7101915Abstract: The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or weakly suppresses the production of IgG, IgM and/or IgA which are produced at the same time, a compound of the formula (I): wherein R1–R13 are hydrogen, halogen, lower alkyl, lower alkoxy or the like, X is —O—, CH2—, —NR14— or —S(O)p— and Y is lower alkyl, lower alkenyl or the like, a process for producing the same and a pharmaceutical composition comprising the same.Type: GrantFiled: July 30, 1997Date of Patent: September 5, 2006Assignee: Shionogi & Co., Ltd.Inventors: Kenji Kawada, Mitsuaki Ohtani, Ryuji Suzuki, Akinori Arimura
-
Patent number: 7074836Abstract: The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or weakly suppresses the production of IgG, IgM and/or IgA which are produced at the same time, a compound of the formula (I): wherein R1–R13 are hydrogen, halogen, lower alkyl, lower alkoxy or the like, X is —O—, —CH2—, NR14— or —S(O)p— and Y is lower alkyl, lower alkenyl or the like, a process for producing the same and a pharmaceutical composition comprising the same.Type: GrantFiled: November 12, 2003Date of Patent: July 11, 2006Assignee: Shionogi & Co., Ltd.Inventors: Kenji Kawada, Mitsuaki Ohtani, Ryuji Suzuki, Akinori Arimura
-
Patent number: 7071234Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.Type: GrantFiled: March 25, 2003Date of Patent: July 4, 2006Assignee: Sepracor Inc.Inventors: Thomas P Jerussi, Chrisantha H. Senanayake, Qun K. Fang
-
Patent number: 7030160Abstract: The invention relates to phenoxypropanolamines, to pharmaceutical compositions containing them, to processes for preparing them, and to the method of use thereof in the treatment of diseases that are improved by beta-3 agonist action.Type: GrantFiled: May 29, 2001Date of Patent: April 18, 2006Assignee: Sanofi-AventisInventors: Laura Barzaghi, Philippe R. Bovy, Roberto Cecchi, Tiziano Croci, Stefano Romagnano
-
Patent number: 6984664Abstract: Disclosed are compounds of the formula (I) wherein R1, R2 R3 R4 R5, R6 and N are as disclosed herein. The compounds are useful for the treatment of chronic and acute pain.Type: GrantFiled: December 6, 2000Date of Patent: January 10, 2006Assignee: Euro-Celtique, S.A.Inventors: Donald Kyle, R Richard Goehring, Sam Victory
-
Patent number: 6974840Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof in which m is 0, 1 or 2; n is 2, 3, 4 or 5; X is carbonyl or a group of formula (II) in which R5 is H or alkyl; Y is an alkylene chain optionally substituted by one or more alkyl groups; Z is an alkylene chain containing 2 to 5 carbon atoms optionally substituted by one or more alkyl groups; R is phenyl optionally substituted by one or more halo substituents or R is naphthyl; and R1 and R2, which are the same or different, are H, alkyl, or arylalkyl, provided that when R1 is benzyl, R2 is H or methyl; have utility in the treatment of drug misuse or other addictive disorders.Type: GrantFiled: June 21, 2000Date of Patent: December 13, 2005Assignee: Knoll GmbHInventors: Graham Paul Luscombe, Patricia Lesley Needham
-
Patent number: 6919482Abstract: Disclosed are multibinding compounds which are ?2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.Type: GrantFiled: January 30, 2004Date of Patent: July 19, 2005Assignee: Theravance, Inc.Inventors: Edmund J. Moran, Seok-Ki Choi
-
Patent number: 6919317Abstract: Synergistic combinations of a squalene epoxidase inhibitor such as terbinafine and a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro, 33-desoxyascomycin are provided, which are useful in particular in the treatment of diseases involving fungal or suspected fungal infection, for immunomodulation or immunosuppression in conditions in which fungal or suspected fungal colonisation of e.g. the skin plays a role, such as atopic dermatitis and seborrhoeic dermatitis, and in situations of fungal resistance.Type: GrantFiled: February 16, 2001Date of Patent: July 19, 2005Assignee: Novartis AGInventors: Neil Stewart Ryder, Friedrich Karl Mayer
-
Patent number: 6881748Abstract: A bioreductive conjugate comprises a bioreductive moiety with at least one therapeutic agent linked thereto and physiologically acceptable derivatives thereof. The bioreductive moiety incorporates an aromatic ring substituted with a nitro group and the conjugate is such that bioreduction of the nitro group causes release of the therapeutic agent by a through bond elimination and the residue of the bioreductive moiety to undergo an intramolecular cyclization reaction in which the nitrogen of the original nitro group provides an atom of the thus formed ring.Type: GrantFiled: August 19, 1999Date of Patent: April 19, 2005Assignee: The Victoria University of ManchesterInventors: Sally Freeman, Mohammed Jaffor, Ian Stratford
-
Patent number: 6872852Abstract: Cytotoxic polyamine analogues are provided that are useful for treating diseases where it is desired to inhibit cell growth and/or proliferation, for example cancer and post-angioplasty injury.Type: GrantFiled: March 23, 2001Date of Patent: March 29, 2005Assignee: MediQuest Therapeutics, Inc.Inventor: Mark R. Burns
-
Patent number: 6846492Abstract: The use of compounds of formula (1) is described, in which compounds R1, R2 and R3 are each independently of the others hydrogen; C1-C20alkyl; C3-C7cycloalkyl; C2-C20alkenyl; C4-C7cycloalkenyl; C2-C20alkynyl, C4-C7cycloalkynyl; or unsubstituted or C1-C5alkyl-, C3-C7cylcoalkyl-, C1-C5alkoxyl-, C3-C7cycloakoxy-, halo-, oxo-, carboxy-, carboxy-C1-C7alkyl ester-, carboxy-C3-C7cylcloalkyl ester-, cyano-, trifluoromethyl-, pentafluoroethyl-, amino-, N,N-mono- or di-C1-C20alkylamino- or nitro-substituted phenyl-C1-C5alkyl, naphthyl-C1-C5alkyl, phenylcarbonyl-C1-C5alkyl, naphthylcarbonyl-C1-C5alkyl, pyrrolylalkyl, furanylalkyl, thiophenylalkyl, pyrazolylalkyl, imidazolylalkyl, oxazolylalkyl, thiazolylalkyl, isoxazolylalkyl, isothiazolylalkyl, 1,2,3-triazolylalkyl, 1,2,4-triazolylalkyl, 1,2,3-oxadiazolylalkyl, 1,3,4-oxadiazolylalkyl, 1,2,3-thiadiazolylalkyl, 1,3,4-thiadiazolylalkyl, indolylalkyl, pyridylalkyl, pyridazinylalkyl, pyrimidinylalkyl, pyridazinylalkyl, quinolinylalkyl, isoquinolinylalkyl, pyrrolyl, furanyl,Type: GrantFiled: February 13, 2001Date of Patent: January 25, 2005Assignee: Ciba Specialty Chemicals CorporationInventors: Wolfgang Haap, Werner Hölzl, Dietmar Ochs, Karin Petzold, Marcel Schnyder
-
Patent number: 6835386Abstract: The present invention provides a device, preferably a collar or ear tag, capable of the controlled, sustained release of an effective amount of an active ingredient that can protect an animal against arthropod pests, comprising a reservoir containing a novel gel formulation comprising a fatty acid, an organic solvent which is a linear aliphatic ester, a silicone-based fluid, or a combination thereof, and an active ingredient that can protect the animal against one or more arthropod pests.Type: GrantFiled: October 18, 2002Date of Patent: December 28, 2004Assignee: Pfizer Inc.Inventor: Luis Gutierrez
-
Publication number: 20040259956Abstract: A titration dosing regimen for the administration of controlled release tramadol analgesic to patients. The titration dosing regimen provides a significant reduction in the occurrence of adverse effects from the introduction of controlled released tramadol dosing, thus increasing patient compliance and medication tolerability.Type: ApplicationFiled: March 10, 2004Publication date: December 23, 2004Inventors: Curtis Wright, Robert Colucci, Raymond Sanchez
-
Publication number: 20040248979Abstract: The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis comprising coadministering to said subject a first amount of an &agr;2&dgr; subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative, wherein the first and second amounts together comprise a therapeutically effective amount.Type: ApplicationFiled: June 3, 2004Publication date: December 9, 2004Applicant: DYNOGEN PHARMACEUTICALS, INC.Inventors: Lee R. Brettman, Steven B. Landau, Matthew O. Fraser
-
Patent number: 6828318Abstract: Compounds of formula (1): wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl, aryl and non-aromatic heterocyclic groups, or each of one or more pair(s) of the substituent groups R1 to R6 may together form a 3,4,5,6,7 or 8-membered ring containing 0,1 or 2 heteroatom(s); R7 is selected from alkyl, aryl and non-aromatic heterocyclic groups; and R8 is selected from hydrogen, halogen, alkyl, aryl and non-aromatic heterocyclic groups; and pharmaceutically acceptable salts and prodrugs thereof, are useful for treating conditions generally associated with abnormalities in glutamatergic transmission.Type: GrantFiled: March 31, 2003Date of Patent: December 7, 2004Assignee: Vernalis Research LimitedInventors: Michael Frederick Snape, Roger John Gillespie, Claire Elizabeth Dawson, Steven Michael McAteer, Suneel Gaur
-
Publication number: 20040225015Abstract: A carba-sugar amine derivative represented by the following formula (1) or (2) is used as the active ingredient of a &bgr;-galactosidase inhibitor or a glycolipid metabolic disorder treating agent.Type: ApplicationFiled: March 8, 2004Publication date: November 11, 2004Applicant: Seikagaku CorporationInventors: Seiichiro Ogawa, Yoshiyuki Suzuki, Eiji Nanba, Junichiro Matsuda, Kousaku Ohno
-
Publication number: 20040220280Abstract: The present invention is directed to forms II, III, V, VI, VII, VIII, IX and X of sertraline hydrochloride and novel methods for their preparation. According to the present invention, sertraline hydrochloride polymorph II may be produced by slurrying sertraline hydrochloride polymorph VI in aprotic organic solvent. Sertraline hydrochloride polymorphic form III may be produced by heating sertraline hydrochloride polymorphs V and VI. Sertraline hydrochloride forms V and VI may be produced from either sertraline hydrochloride or sertraline base by crystallization. Sertraline hydrochloride Form VII may be produced by suspending sertraline chloride polymorph V in water, followed by filtration. Sertraline hydrochloride Forms VIII and IX may be produced by suspending sertraline base in water followed by acidification and filtration. Sertraline hydrochloride Form X may be produced by suspending sertraline hydrochloride in benzyl alcohol with heating, followed by filtration.Type: ApplicationFiled: June 4, 2004Publication date: November 4, 2004Inventors: Eduard Schwartz, Tamar Nidam, Anita Liberman, Marioara Mendelovici, Judith Aronhime, Claude Singer, Evgeni Valdman
-
Publication number: 20040220279Abstract: The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized from new solvent systems. Pharmaceutical compositions containing sertraline hydrochloride Form II and methods of treatment using such pharmaceutical compositions are also disclosed.Type: ApplicationFiled: June 4, 2004Publication date: November 4, 2004Inventors: Eduard Schwartz, Tamar Nidam, Anita Liberman, Marioara Mendelovici, Judith Aronhime
-
Publication number: 20040214822Abstract: 4-aminocyclohexanol compounds, processes for their preparation, pharmaceutical formulations comprising these compounds and the use of substituted 4-aminocyclohexanol compounds for the preparation of pharmaceutical formulations and for the treatment of diverse indications, including, without limitation, pain.Type: ApplicationFiled: January 16, 2004Publication date: October 28, 2004Applicant: Gruenenthal GmbHInventors: Bernd Sundermann, Hagen-Heinrich Hennies, Babette-Yvonne Koegel, Stephan Wnendt
-
Publication number: 20040198837Abstract: A compound of formula I 1Type: ApplicationFiled: April 21, 2004Publication date: October 7, 2004Inventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein, Edward Chong
-
Publication number: 20040180966Abstract: The present invention provides enantiomers of N-Desmethyl venlafaxine, as well as their use in pharmaceutical compositions and medically useful treatments, particularly including central nervous system uses.Type: ApplicationFiled: March 29, 2004Publication date: September 16, 2004Applicant: WyethInventors: John P. Yardley, Andre A. Asselin
-
Publication number: 20040171696Abstract: The compounds of the general Formula (I) (wherein R stands for hydrogen or methyl) can be used for the treatment or prophylaxis of diseases characterized either by the decline and/or damage of cognitive functions, or mental disability accompanying other diseases. As compound of the general Formula I preferably -(1R,2S,4R)-(−)-2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethylbicyclo[2.2.1]heptane-fumarate can be used.Type: ApplicationFiled: April 15, 2004Publication date: September 2, 2004Inventors: Istvan Gacsalyi, Gyorgy Levay, Ildiko Nagyne Gyonos, Laszlo Gabor Harsing
-
Publication number: 20040162355Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.Type: ApplicationFiled: February 3, 2004Publication date: August 19, 2004Applicant: Sepracor Inc.Inventor: Thomas P. Jerussi
-
Publication number: 20040138313Abstract: The invention relates to compounds of the formula (I) 1Type: ApplicationFiled: July 25, 2003Publication date: July 15, 2004Applicant: Aventis Pharma Deutschland GmbHInventors: Claudia Eder, Herbert Kogler, Sabine Haag-Richter
-
Publication number: 20040127550Abstract: The invention relates to a medicament containing an effector of the glutathione metabolism together with &agr;-lipoic acid, its salts and/or prodrugs as a combined preparation for the simultaneous, separate or time-controlled treatment of a defective thiol-disulfide status in kidney replacement therapy and of clinical characteristics, which indicate a disorder of the thiol-disulfide status of immunocytes. The correction of a defective thiol metabolism is of fundamental importance as a basic therapy for treating a large number of diseases of different origin, in particular however in circumstances requiring an essential kidney replacement therapy.Type: ApplicationFiled: November 26, 2003Publication date: July 1, 2004Inventors: Michael Tager, Siegfried Ansorge, Gerhard Frics, Dieter Koegst
-
Patent number: 6756508Abstract: The present invention relates to new cinnamic acid salts of salmeterol, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions.Type: GrantFiled: February 13, 2003Date of Patent: June 29, 2004Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Guenter Linz, Rainer Soyka
-
Methods of treating and preventing narcolepsy using enantiomerically pure (s)-didesmethylsibutramine
Publication number: 20040116534Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.Type: ApplicationFiled: November 21, 2003Publication date: June 17, 2004Applicant: Sepracor, Inc.Inventor: Thomas P. Jerussi -
Publication number: 20040097547Abstract: There are disclosed compounds of the formula 1Type: ApplicationFiled: July 30, 2002Publication date: May 20, 2004Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Kingsley H. Nelson, Laura L. Rokosz
-
Publication number: 20040092481Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.Type: ApplicationFiled: October 28, 2003Publication date: May 13, 2004Applicant: Sepracor, Inc.Inventor: Thomas P. Jerussi
-
Publication number: 20040087644Abstract: The present invention is referred as a formula or combination of two compounds, one of them being a non-steroidal anti-inflammatory such as ketorolac, and the other an opiate analgesic known as tramadol, which are formulated in capsules.Type: ApplicationFiled: June 24, 2003Publication date: May 6, 2004Applicant: Leopoldo Espinosa AbdalaInventors: Maria Elena Garcia Armenta, Victor Guillermo Alvarez Ochoa, Josefina Santos Murillo
-
Patent number: 6730329Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.Type: GrantFiled: February 26, 2002Date of Patent: May 4, 2004Inventor: Jeffrey B. Smith
-
Publication number: 20040082665Abstract: A method of treating stress and/or tension in a mammal by administering to the mammal an effective amount of 1,7,7-trimethyl-bicyclo[2.2.Type: ApplicationFiled: July 21, 2003Publication date: April 29, 2004Inventor: Outi Maki-Ikola
-
Publication number: 20040077730Abstract: A compound of formula I 1Type: ApplicationFiled: August 15, 2003Publication date: April 22, 2004Inventors: Clifford James Bailey, Robert Brian Jones, Helen Christine Jackson
-
Publication number: 20040076669Abstract: The invention relates to a medicament containing the racemate of tramadol in a retarded form and the (+)-enantiomer of tramadol in a non-retarded form.Type: ApplicationFiled: August 15, 2003Publication date: April 22, 2004Inventors: Johannes Bartholomaus, Elmar Josef Friderichs
-
Publication number: 20040072854Abstract: A NK1 antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough: 1Type: ApplicationFiled: March 12, 2003Publication date: April 15, 2004Applicant: Schering CorporationInventors: Michelle Laci Wrobleski, Gregory A. Reichard, Neng-Yang Shih, Dong Xiao
-
Publication number: 20040067986Abstract: Neuro-metabolic and endocrine-function regulating/modulating compositions, are disclosed. The compositions of the present invention comprise Selegiline Hydrochloride, Procaine Hydrochloride, Vinpocetine, trimethylglycine, and an ingredient selected from a group consisting of N-nicotinoyl-gamma-aminobutyric acid (N-GABA), niacin, niacinamide, gamma-aminobutyric acid (GABA), and combinations thereof. Methods of using the compositions, compositions, and compositions of the present invention are also disclosed.Type: ApplicationFiled: March 5, 2003Publication date: April 8, 2004Inventor: Nathan Sassover
-
Publication number: 20040068018Abstract: The present invention relates to a pharmaceutical composition for treating or preventing obesity, comprising novel crystalline sibutramine methanesulfonate hemihydrate of formula (I). The crystalline sibutramine methanesulfonate hemihydrate according to the present invention has a much higher solubility in water, and enhanced stability under a high humidity/temperature condition, as compared with sibutramine hydrochloride monohydrate.Type: ApplicationFiled: October 3, 2003Publication date: April 8, 2004Inventors: Jae-Heon Lee, Gha-Seung Park, Jae-Cheol Lee, Han-Kyong Kim, Young-Kil Chang, Gwan-Sun Lee
-
Publication number: 20040059003Abstract: The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.Type: ApplicationFiled: September 25, 2002Publication date: March 25, 2004Applicant: Innovative Drug Delivery Systems, Inc.Inventors: Fred H. Mermelstein, Randi Albin
-
Patent number: 6710080Abstract: Substituted 2-dialkylaminoalkylbiphenyl derivatives, processes for their preparation, pharmaceutical compositions comprising these compounds and methods using these compounds for the preparation of medicaments and for the treatment of diseases.Type: GrantFiled: February 11, 2002Date of Patent: March 23, 2004Assignee: Gruenenthal GmbHInventors: Bernd Sundermann, Babette-Yvonne Koegel, Helmut Buschmann
-
Publication number: 20040048856Abstract: The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.Type: ApplicationFiled: September 4, 2003Publication date: March 11, 2004Applicant: Pfizer IncInventors: Harry R. Howard, Christopher J. Schmidt, Thomas F. Seeger, Mark L. Elliott
-
Patent number: RE39221Abstract: This invention relates to a composition comprising a tramadol material and acetaminophen, and its use. As used herein tramadol refers to various forms of tramadol. The compositions are pharmacologically useful in treating pain and tussive conditions. The compositions are also subject to less opioid side-effects such as abuse liability, tolerance, constipation and respiratory depression. Furthermore, where the components of the compositions are within certain ratios the pharmacological effects of the compositions are superadditive (synergistic).Type: GrantFiled: January 20, 2004Date of Patent: August 1, 2006Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Robert B. Raffa, Jeffrey L. Vaught